Virginia Cancer Specialists

What Virginia Cancer Specialists does

Virginia Cancer Specialists (VCS) is a private community oncology practice headquartered in Fairfax, Virginia, founded in 1972 and operating as part of the US Oncology Network. It is the largest private cancer practice in Northern Virginia, with 14 office locations serving the Northern Virginia and broader Mid-Atlantic region and a headcount of 251-500 staff including physicians, nurse practitioners, physician assistants, genetic counselors, oncology social workers, and registered dietitians. The practice provides comprehensive cancer care across medical oncology, radiation oncology, surgical oncology, chemotherapy, immunotherapy, targeted therapy, CAR T-cell therapy, and radiopharmaceutical treatments. Through its VCS Research Institute, VCS operates the largest oncology research program in the Mid-Atlantic with 200+ actively enrolling clinical trials, in partnership with NEXT Oncology and Sarah Cannon Research Institute.

The technology stack is anchored by advanced radiation delivery systems — TrueBeam linear accelerator, Nucletron microSelectron Digital HDR brachytherapy unit, IMRT, IGRT, SBRT, SRS, VMAT, and 3D-CRT — and a Center for Theranostics Research that delivers radiopharmaceutical treatments for prostate cancer and neuroendocrine tumors. Other core offerings include a Molecular Tumor Board for personalized treatment selection, a Paxman scalp cooling system for chemotherapy-induced hair loss, hereditary cancer risk assessment, a CAR T-Cell Therapy Program, and supportive/palliative care. VCS holds multiple national designations: ASTRO Authorized User Training Center (one of the first two in the U.S.), SNMMI Radiopharmaceutical Center of Excellence, ASTRO APEX accreditation, and NCODA Center of Excellence MIP accreditation.

VCS generates revenue primarily through insurance-billed patient care services, with co-payments collected at time of service, plus income from clinical trial participation with pharmaceutical sponsors via the VCS Research Institute. The practice is physician-owned and operated, participates with major insurance plans, and has no disclosed external private equity or venture capital investment. Patient acquisition occurs through 14 community-based offices, online appointment requests via the HealthViewX platform, physician referrals, and a physician liaison program. Key differentiators include the 200+ trial research footprint, theranostics capability, and three consecutive years of Castle Connolly #1 ranking for cancer care in Virginia.

Name

Virginia Cancer Specialists

Legal name

Virginia Cancer Specialists

Website

https://virginiacancerspecialists.com

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

251–500 employees

Short description

Virginia Cancer Specialists is a private community oncology practice and the largest private cancer practice in Northern Virginia, operating 14 locations and serving cancer patients with medical, radiation, and surgical oncology, plus 200+ clinical trials through its VCS Research Institute.

Ownership category

akta.pro rank

Product category

Oncology Services

NAICS

Offices of Physicians (62111), Ambulatory Health Care Services (621)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Surgical Oncology (HLAKAFAG)

Keywords

• Oncology treatment services
• Radiation oncology therapy
• Clinical trials research
• Cancer care practice
• Surgical oncology services

Headquarters

HQ city

Fairfax

HQ country

United States

HQ region

North America

Offices14 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Patient Care Services: Medical oncology, radiation oncology, surgical oncology, and supportive cancer care services billed to insurance. Co-payments collected at time of service. The practice participates with insurance plans and files claims on behalf of patients.
2. Clinical Trial Services: Research institute offering 200+ clinical trials for various cancer types and mutations. Participation in clinical research programs with pharmaceutical partners.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Virginia Cancer Specialists provides comprehensive community-based cancer care including medical oncology, radiation oncology, surgical oncology (breast, thoracic, musculoskeletal), chemotherapy, immunotherapy, targeted therapy, CAR T-cell therapy, and radiopharmaceutical treatments. The practice operates the VCS Research Institute offering 200+ clinical trials and houses the Center for Theranostics Research. It serves patients across 14 locations throughout Northern Virginia.

Product overview

Virginia Cancer Specialists is the largest private cancer practice in Northern Virginia offering a comprehensive, integrated oncology care platform. The practice operates through specialized treatment teams (Brain Tumor, Breast Cancer, Lung Cancer, Sarcoma, etc.) supported by core service lines including Medical Oncology, Radiation Oncology, Immunotherapy, Targeted Therapy, and CAR T-Cell Therapy. The VCS Research Institute serves as the central hub, providing access to 200+ clinical trials through partnerships with NEXT Oncology and Sarah Cannon Research Institute. Supporting services include Hereditary Cancer Risk Assessment, Molecular Tumor Board for personalized medicine, Supportive/Palliative Care, and the Paxman Scalp Cooling system for hair preservation. The practice also houses a Center for Theranostics Research offering radiopharmaceutical treatments including Pluvicto for prostate cancer. Multiple locations throughout Northern Virginia provide community-based access to cutting-edge treatments.

Differentiator

Problem solved

Functional benefit

Brands

• VCS Research Institute: The research institute of Virginia Cancer Specialists, described as the largest oncology research program in the Mid-Atlantic region with 200+ actively enrolling clinical trials.
• Center for Theranostics Research

Products and services

• Brain Tumor and Neuro-Oncology Team Specialized neuro-oncology and radiation oncology team providing personalized treatment plans for brain and spinal cord malignancies including primary brain tumors and metastases, using advanced technologies and clinical trial access.
• Breast Cancer Team Comprehensive breast cancer care including medical oncology, surgery, radiation, genetic testing, and reconstruction services delivered by a multidisciplinary team of specialists.
• Breast Surgery Services Full spectrum breast surgery including advanced axillary techniques, hidden scar procedures, oncoplastic surgery, skin-sparing mastectomy, and lymphovenous anastomosis for lymphedema prevention.
• CAR T-Cell Therapy Program Personalized cancer treatment that modifies patient's own T-cells to recognize and target cancer cells, offered as a one-time infusion procedure for eligible blood cancer patients.
• Chemotherapy Anticancer drug treatment administered orally or intravenously, with personalized treatment plans developed by medical oncologists and ongoing monitoring for side effects.
• Hereditary Cancer Risk Assessment Genetic counseling and testing services to identify inherited cancer risks, with personalized screening and prevention recommendations based on family history and genetic mutations.
• Immunotherapy Immuno-oncology treatments that harness the body's immune system to fight cancer, with access to FDA-approved therapies and clinical trials through US Oncology Network.
• Lung Cancer and Thoracic Oncology Program Multidisciplinary lung and thoracic cancer care including medical oncology, surgery, radiation, molecular testing, and access to clinical trials through NEXT Oncology partnership.
• Medical Oncology Cancer treatment coordination using medicines including chemotherapy, hormones, and analgesics, with personalized treatment plans and ongoing patient monitoring.
• Molecular Tumor Board - Personalized Medicine Multidisciplinary tumor board utilizing molecular profiling and genomic biomarker testing to match patients with targeted therapies and appropriate clinical trials.
• Musculoskeletal Tumor Surgery Orthopedic oncology services for sarcoma and soft tissue tumors including limb-sparing surgery, endoprosthetic reconstruction, and complex pelvic/hip procedures.
• Radiation Oncology/Therapy Advanced radiation therapy including TrueBeam, SRS/SBRT, IMRT, VMAT, IGRT, 3D-CRT, and HDR brachytherapy, delivered at the Center for Theranostics Research.
• Radiopharmaceutical Prostate Cancer Treatment (Pluvicto) PSMA-targeted radiopharmaceutical therapy combining PET imaging with Pluvicto treatment for metastatic castration-resistant prostate cancer.
• Supportive Cancer Care Palliative care services providing symptom management, emotional support, and quality of life improvement for patients at all stages of cancer treatment.
• Targeted Therapy Molecularly targeted cancer therapies blocking specific molecules involved in tumor growth and progression, based on genetic and cellular analysis of individual tumors.
• VCS Research Institute - Clinical Trials Largest oncology research program in the Mid-Atlantic region offering 200+ actively enrolling clinical trials for nearly every cancer type and mutation, through partnerships with NEXT Oncology and Sarah Cannon Research Institute.

Quantifiable outcome

• Nearly 90% disease control rate in KRAS-mutated pancreatic cancer with daraxonrasib targeted therapy
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• NEXT OncologycoreStrategic or Co-development PartnerVirginia Cancer Specialists Research Institute partnered with NEXT Oncology-Virginia to expand Phase 1 clinical trial programs. This partnership has resulted in development of numerous new drugs and therapeutics, providing patients access to cutting-edge treatments in the community setting.
• Sarah Cannon Research Institute (SCRI)coreStrategic or Co-development PartnerPartnership with globally renowned Sarah Cannon Research Institute for cancer drug development and access to breakthrough therapies. Extends clinical trial options and research capabilities for patients.
• US Oncology NetworkcoreStrategic or Co-development PartnerVirginia Cancer Specialists is part of the US Oncology Network, which provides access to clinical trials, best practices, group purchasing power, and practice management support. The network includes thousands of physicians focused on advancing cancer care.
• Cartography BiosciencesminorStrategic or Co-development PartnerClinical trial partnership where Virginia Cancer Specialists/NEXT Oncology in Fairfax, Virginia serves as a trial site for Cartography Biosciences' Phase 1 clinical trial of CBI-1214, a T-cell engager for colorectal cancer treatment.
• NEXT OncologycoreStrategic or Co-development PartnerVirginia Cancer Specialists and NEXT Oncology jointly provided therapy through their research program in the community setting for the landmark daraxonrasib study for KRAS-mutated pancreatic cancer published in The New England Journal of Medicine.
• American Society for Radiation Oncology (ASTRO)coreStrategic or Co-development PartnerSelected by ASTRO as one of the first two Authorized User Training Centers in the United States to address gap in radiopharmaceutical therapy training access. Allows radiation oncologists nationwide to complete required supervised cases.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Texas Oncology: Largest community oncology practice in Texas and a core member of the US Oncology Network, offering medical oncology, radiation oncology, surgical oncology, and a large clinical trials program. Most directly comparable peer given shared US Oncology affiliation, multi-site community model, and trial scale.
• Florida Cancer Specialists & Research Institute: Large community oncology practice operating numerous sites across Florida with medical oncology, radiation oncology, hematology, imaging, and a substantial clinical trials program. Comparable scale, multi-specialty community model, and emphasis on research.
• Maryland Oncology Hematology: Mid-Atlantic community oncology practice within the US Oncology Network offering medical oncology, hematology, infusion, and clinical trials. Directly comparable as a regional community oncology peer sharing the same parent network.
• New York Cancer & Blood Specialists: Multi-site community oncology and hematology practice serving the New York metro with medical oncology, radiation oncology, infusion, and clinical research. Comparable in multi-specialty community oncology delivery and trial participation.
• Rocky Mountain Cancer Centers: Colorado-based community oncology group and US Oncology Network member providing medical oncology, radiation oncology, infusion and clinical trials. Comparable community oncology delivery model with similar research scale.

Broad incumbents

• Inova Schar Cancer Institute: System-affiliated cancer program within Inova Health System serving Northern Virginia with medical, radiation and surgical oncology plus clinical trials. Most direct large competitor in VCS's home market, with deeper hospital-based infrastructure.
• MedStar Georgetown Lombardi Comprehensive Cancer Center: NCI-designated academic cancer center in the DC metro offering medical, radiation, and surgical oncology with extensive clinical research. Competes for complex cases and clinical trial patients within the same catchment.
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: NCI-designated academic cancer center in the Baltimore-DC corridor with deep subspecialty programs and clinical research. Competes for complex oncology referrals and top sub-specialist talent from the same Mid-Atlantic region.

Others

• Sarah Cannon Research Institute: Strategic research partner of VCS and one of the largest community-based clinical trial organizations in the US. Relevant as a research collaboration peer and indirect competitor for clinical trial enrollment.
• NEXT Oncology: Phase I-focused oncology research network and core VCS partner. Functions as a research collaboration peer and indirect competitor for early-phase trial enrollment in the community setting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vcspecialists
• Facebookfacebook.com/virginiacancerspecialists
• LinkedInlinkedin.com/company/virginia-cancer-specialists-p-c-

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virginia Cancer Specialists